Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on sleep in brain health

LIVE: Thursday 2nd May 2024, 18:00-19:30 (CEST)

Quality sleep is essential for health. But what happens to our brains when sleep patterns are disturbed? Join our experts to explore the interplay between sleep disruption and neurological diseases, and the questions that you need to be asking your patients to help you prevent the harmful effects of sleep deprivation.
ADVANCED SEARCH
Log in
Top
Immunologic Research
Published in: Immunologic Research 2/2018

01-04-2018 | Review

Pemphigus group: overview, epidemiology, mortality, and comorbidities

Author: Khalaf Kridin

Published in: Immunologic Research | Issue 2/2018

Login to get access

Abstract

Pemphigus forms a group of rare autoimmune bullous diseases that affect the skin and mucous membranes. This group has a chronic course leading to high morbidity and mortality. It is characterized by the production of pathogenic autoantibodies directed against different proteins of the desmosome, leading histologically to intraepidermal cleavage, and clinically to vesicles and erosions on the epithelium of the mucous membranes and/or the skin. The diagnosis of the subtype of pemphigus is based on clinical features, the level of histologic cleavage, and the identification of the antigens recognized by circulating autoantibodies by immunoserological analyses. The epidemiological features of pemphigus vary considerably in different regions of the world. Observational studies examining comorbidities and associations among patients with pemphigus are scarce and sometimes inconclusive. The prognosis, mortality, and clinical outcomes in pemphigus have undergone dramatic change throughout the years. This review provides a brief overview about the different subtypes of pemphigus: pemphigus vulgaris, pemphigus foliaceus, paraneoplastic pemphigus, pemphigus herpetiformis, and IgA pemphigus. In addition, it summarizes the most recent understanding of the epidemiology, mortality data, and comorbidities of this group of organ-specific autoimmune diseases.
Literature
1.
2.
Hsu DY, Brieva J, Sinha AA, Langan SM, Silverberg JI. Comorbidities and inpatient mortality for pemphigus in the USA. Br J Dermatol. 2016;174:1290–8.CrossRefPubMed
3.
4.
Pan M, Liu X, Zheng J. The pathogenic role of autoantibodies in pemphigus vulgaris. Clin. Exp. Dermatol. 2011. p. 703–7.
5.
Joly P, Litrowski N. Pemphigus group (vulgaris, vegetans, foliaceus, herpetiformis, brasiliensis). Clin Dermatol. 2011;29:432–6.CrossRefPubMed
6.
Amber KT, Staropoli P, Shiman MI, Elgart GW, Hertl M. Autoreactive T cells in the immune pathogenesis of pemphigus vulgaris. Exp Dermatol. 2013;22:699–704.CrossRefPubMed
7.
Bystryn JC, Rudolph JL. Pemphigus. Lancet. 2005. p. 61–73.
8.
9.
Amagai M, Hashimoto T, Shimizu N, Nishikawa T. Absorption of pathogenic autoantibodies by the extracellular domain of pemphigus vulgaris antigen (Dsg3) produced by baculovirus. J Clin Invest. 1994;94:59–67.CrossRefPubMedPubMedCentral
10.
Ahmed AR, Blose DA. Pemphigus vegetans: Neumann type and Hallopeau type. Int J Dermatol. 1984;23:135–41.CrossRefPubMed
11.
Becker BA, Gaspari AA. Pemphigus vulgaris and vegetans. Dermatol Clin. 1993;11:429–52.PubMed
12.
Hietanen J, Salo OP. Pemphigus: an epidemiological study of patients treated in Finnish hospitals between 1969 and 1978. Acta Derm Venereol. 1982;62:491–6.PubMed
13.
Pisanti S, Sharav Y, Kaufman E, Posner LN. Pemphigus vulgaris: incidence in Jews of different ethnic groups, according to age, sex, and initial lesion. Oral Surg Oral Med Oral Pathol. 1974;38:382–7.CrossRefPubMed
14.
Simon DG, Krutchkoff D, Kaslow RA, Zarbo R. Pemphigus in Hartford County, Connecticut, from 1972 to 1977. Arch Dermatol. 1980;116:1035–7.CrossRefPubMed
15.
16.
17.
18.
Micali G, Musumeci ML, Nasca MR. Epidemiologic analysis and clinical course of 84 consecutive cases of pemphigus in eastern Sicily. Int J Dermatol. 1998;37:197–200.CrossRefPubMed
19.
Tsankov N, Vassileva S, Kamarashev J, Kazandjieva J, Kuzeva V. Epidemiology of pemphigus in Sofia, Bulgaria. A 16-year retrospective study (1980–1995). Int J Dermatol. 2000;39:104–8.CrossRefPubMed
20.
Tallab T, Joharji H, Bahamdan K, Karkashan E, Mourad M, Ibrahim K. The incidence of pemphigus in the southern region of Saudi Arabia. Int J Dermatol. 2001;40:570–2.CrossRefPubMed
21.
Hahn-Ristic K, Rzany B, Amagai M, Bröcker EB, Zillikens D. Increased incidence of pemphigus vulgaris in southern Europeans living in Germany compared with native Germans. J Eur Acad Dermatol Venereol. 2002;16:68–71.CrossRefPubMed
22.
Nanda A, Dvorak R, Al-Saeed K, Al-Sabah H, Alsaleh QA. Spectrum of autoimmune bullous diseases in Kuwait. Int J Dermatol. 2004;43:876–81.CrossRefPubMed
23.
Chams-Davatchi C, Valikhani M, Daneshpazhooh M, Esmaili N, Balighi K, Hallaji Z, et al. Pemphigus: analysis of 1209 cases. Int J Dermatol. 2005;44:470–6.CrossRefPubMed
24.
Golušin Z, Poljački M, Jovanović M, Duran V, Stojanović S, Rajić N. Some epidemiological features of pemphigus chronicus in South Vojvodina: a 12-year retrospective study [2]. Int. J. Dermatol. 2005. p. 792–3.
25.
26.
27.
Michailidou EZ, Belazi MA, Markopoulos AK, Tsatsos MI, Mourellou ON, Antoniades DZ. Epidemiologic survey of pemphigus vulgaris with oral manifestations in northern Greece: retrospective study of 129 patients. Int J Dermatol. 2007;46:356–61.CrossRefPubMed
28.
V’lckova-Laskoska MT, Laskoski DS, Kamberova S, Caca-Biljanovska N, Volckova N. Epidemiology of pemphigus in Macedonia: a 15-year retrospective study (1990–2004). Int J Dermatol. 2007;46:253–8.CrossRefPubMed
29.
30.
Kumar KA. Incidence of pemphigus in Thrissur district, south India. Indian J Dermatol Venereol Leprol. 2008;74:349–51.CrossRefPubMed
31.
32.
Marazza G, Pham HC, Schärer L, Pedrazzetti PP, Hunziker T, Trüeb RM, et al. Incidence of bullous pemphigoid and pemphigus in Switzerland: A 2-year prospective study. Br. J Dermatol. 2009;161:861–8.CrossRefPubMed
33.
Baican A, Baican C, Chiriac G, Chiriac MT, Macovei V, Zillikens D, et al. Pemphigus vulgaris is the most common autoimmune bullous disease in northwestern Romania. Int J Dermatol. 2010;49:768–74.CrossRefPubMed
34.
35.
Marinovic B, Lipozencic J, Jukic IL. Autoimmune blistering diseases: incidence and treatment in Croatia. Dermatol. Clin. 2011. p. 677–9.
36.
37.
38.
39.
Milinković M V., Janković S, Medenica L, Nikolić M, Reljić V, Popadić S, et al. Incidence of autoimmune bullous diseases in Serbia: a 20-year retrospective study. JDDG J. der Dtsch. Dermatologischen Gesellschaft [Internet]. 2016 [cited 2017 Sep 3];14:995–1005. Available from: http://​www.​ncbi.​nlm.​nih.​gov/​pubmed/​27767273
40.
41.
42.
Ahmed AR, Yunis EJ, Khatri K, Wagner R, Notani G, Awdeh Z, et al. Major histocompatibility complex haplotype studies in Ashkenazi Jewish patients with pemphigus vulgaris. Proc Natl Acad Sci U S A. 1990;87:7658–62.CrossRefPubMedPubMedCentral
43.
44.
Mobini N, Yunis EJ, Alper CA, Yunis JJ, Delgado JC, Yunis DE, et al. Identical MHC markers in non-Jewish Iranian and Ashkenazi Jewish patients with pernphigus vulgaris: possible common central Asian ancestral origin. Hum Immunol. 1997;57:62–7.CrossRefPubMed
45.
46.
47.
Risser J, Lewis K, Weinstock MA. Mortality of bullous skin disorders from 1979 through 2002 in the United States. Arch Dermatol. 2009;145:1005–8.CrossRefPubMed
48.
49.
Anhalt GJ. Making sense of antigens and antibodies in pemphigus. J Am Acad Dermatol. 1999;40:763–6.CrossRefPubMed
50.
Mahoney MG, Wang Z, Rothenberger K, Koch PJ, Amagai M, Stanley JR. Explanations for the clinical and microscopic localization of lesions in pemphigus foliaceus and vulgaris. J Clin Invest. 1999;103:461–8.CrossRefPubMedPubMedCentral
51.
Scott JE, Ahmed AR. The blistering diseases. Med Clin North Am. 1998. p. 1239–83.
52.
53.
Amerian ML, Ahmed AR. Pemphigus erythematosus: Senear-Usher syndrome. Int. J. Dermatol. 1985. p. 16–25.
54.
55.
Korman NJ. New immunomodulating drugs in autoimmune blistering diseases. Dermatol Clin. 2001. p. 637–48.
56.
Amagai M. Pemphigus. In: Bolognia JL, Jorizzo JL, Schaffer J V, editors. Dermatology. Third. Elsevier; 2012. p. 461–73.
57.
Abreau-Velez AM, Hashimoto T, Bollag WB, Arroyave ST, Abreau-Velez CE, Londoeo ML, et al. A unique form of endemic pemphigus in northern Colombia. J Am Acad Dermatol. 2003;49:599–608.CrossRef
58.
Stanley J. Pemphigus. In: Wolff K, Goldsmith LA, Katz SI, et al., editors. Fitzpatrick’s dermatology in general medicine. New York, McGraw-Hill; 2008. p. 459–68.
59.
Del Mar Sáez-de-Ocariz M, Vega-Memije ME, Zúñiga J, Salgado N, Ruíz J, Balbuena A, et al. HLA-DRB1*0101 is associated with foliaceous pemphigus in Mexicans. Int. J. Dermatol. 2005. p. 350.
60.
De Sena Nogueira Maehara L, De-Souza-Santana FC, Porro AM, Marcos EVC, Ura S, Nolte IM, et al. HLA class II alleles of susceptibility and protection in Brazilian and Dutch pemphigus foliaceus. Br. J. Dermatol. [Internet]. 2017 [cited 2017 Nov 25]; Available from: https://​doi.​org/​10.​1111/​bjd.​16022
61.
62.
Loiseau P, Lecleach L, Prost C, Lepage V, Busson M, Bastuji-Garin S, et al. HLA class II polymorphism contributes to specify desmoglein derived peptides in pemphigus vulgaris and pemphigus foliaceus. J Autoimmun. 2000;15:67–73.CrossRefPubMed
63.
Diaz LA, Sampaio SA, Rivitti EA, Martins CR, Cunha PR, Lombardi C, et al. Endemic pemphigus foliaceus (fogo selvagem). I. Clinical features and immunopathology. J Am Acad Dermatol. 1989;20:657–69.CrossRefPubMed
64.
Empinotti JC, Aoki V, Filgueira A, Sampaio SAP, Rivitti EA, Sanches JA, et al. Clinical and serological follow-up studies of endemic pemphigus foliaceus (fogo selvagem) in western Parana, Brazil (2001–2002). Br J Dermatol. 2006;155:446–50.CrossRefPubMed
65.
Culton DA, Qian Y, Li N, Rubenstein D, Aoki V, Filhio GH, et al. Advances in pemphigus and its endemic pemphigus foliaceus (fogo selvagem) phenotype: a paradigm of human autoimmunity. J Autoimmun. 2008;31:311–24.CrossRefPubMedPubMedCentral
66.
Diaz LA, Arteaga LA, Hilario-Vargas J, Valenzuela JG, Li N, Warren S, et al. Anti-desmoglein-1 antibodies in onchocerciasis, leishmaniasis and chagas disease suggest a possible etiological link to fogo selvagem. J Invest Dermatol. 2004;123:1045–51.CrossRefPubMed
67.
Qian Y, Clarke SH, Aoki V, Hans-Filhio G, Rivitti EA, Diaz LA. Antigen selection of anti-DSG1 autoantibodies during and before the onset of endemic pemphigus foliaceus. J Invest Dermatol. 2009;129:2823–34.CrossRefPubMedPubMedCentral
68.
69.
Robledo MA, Prada S, Jaramillo D, Leon W. South American pemphigus foliaceus: study of an epidemic in El Bagre and Nechi, Colombia 1982 to 1986. Br. J Dermatol. 1988;118:737–44.CrossRefPubMed
70.
Abida O, Zitouni M, Kallel-Sellami M, Mahfoudh N, Kammoun A, Ben Ayed M, et al. Tunisian endemic pemphigus foliaceus is associated with the HLA-DR3 gene: anti-desmoglein 1 antibody-positive healthy subjects bear protective alleles. Br J Dermatol. 2009;161:522–7.CrossRefPubMed
71.
Abida O, Masmoudi A, Rebaï A, Ben Ayed M, Mahfoudh N, Kallel-Sellami M, et al. The familial feature of Tunisian endemic pemphigus foliaceus. Br. J. Dermatol. 2009. p. 951–3.
72.
Joly P, Mokhtar I, Gilbert D, Thomine E, Fazza B, Bardi R, et al. Immunoblot and immunoelectronmicroscopic analysis of endemic Tunisian pemphigus. Br J Dermatol. 1999;140:44–9.CrossRefPubMed
73.
Kallel Sellami M, Ben Ayed M, Mouquet H, Drouot L, Zitouni M, Mokni M, et al. Anti-desmoglein 1 antibodies in Tunisian healthy subjects: arguments for the role of environmental factors in the occurrence of Tunisian pemphigus foliaceus. Clin Exp Immunol. 2004;137:195–200.CrossRefPubMedPubMedCentral
74.
Leshem YA, Katzenelson V, Yosipovitch G, David M, Mimouni D. Autoimmune diseases in patients with pemphigus and their first-degree relatives. Int J Dermatol. 2011;50:827–31.CrossRefPubMed
75.
Parameswaran A, Attwood K, Sato R, Seiffert-Sinha K, Sinha AA. Identification of a new disease cluster of pemphigus vulgaris with autoimmune thyroid disease, rheumatoid arthritis and type I diabetes. Br J Dermatol. 2015;172:729–38.CrossRefPubMed
76.
77.
Kridin K, Zelber-Sagi S, Comaneshter D, Cohen AD. Ulcerative colitis associated with pemphigus: a population-based large-scale study. Scand J Gastroenterol. 2017;52:1360–4.CrossRefPubMed
78.
Firooz A, Mazhar A, Ahmed AR. Prevalence of autoimmune diseases in the family members of patients with pemphigus vulgaris. J Am Acad Dermatol. 1994;3:434–7.CrossRef
79.
80.
81.
82.
83.
84.
85.
86.
87.
88.
89.
90.
91.
92.
93.
94.
95.
Ogawa H, Sakuma M, Morioka S, Kitamura K, Sasai Y, Imamura S, et al. The incidence of internal malignancies in pemphigus and bullous pemphigoid in Japan. J Dermatol Sci. 1995;9:136–41.CrossRefPubMed
96.
Schulze F, Neumann K, Recke A, Zillikens D, Linder R, Schmidt E. Malignancies in pemphigus and pemphigoid diseases. J. Invest. Dermatol. [Internet]. 2015 [cited 2017 Apr 14];135:1445–7. Available from: https://​ssl.​haifa.​ac.​il/​S0022202X1537241​9/​,DanaInfo=.aadBhpxEjlwJn0z+1-s2.0-S0022202X15372419-main.pdf?_tid=48c2b632-211b-11e7-ab18-00000aab0f26&acdnat=1492178852_19abf9717daebe91b688e3cbd8fcbc2e
97.
98.
99.
Kridin K, Zelber-Sagi S, Comaneshter D, Cohen AD. Association between schizophrenia and an autoimmune bullous skin disease-pemphigus: a population-based large-scale study. Epidemiol. Psychiatr. Sci. [Internet]. 2017 [cited 2017 Dec 2];1–8. Available from: http://​www.​ncbi.​nlm.​nih.​gov/​pubmed/​28942756
100.
Wohl Y, Mashiah J, Kutz A, Hadj-Rabia S, Cohen AD. Pemphigus and depression comorbidity: a case control study. Eur J Dermatology. 2015;25:602–5.
101.
Kumar V, Mattoo SK, Handa S. Psychiatric morbidity in pemphigus and psoriasis: a comparative study from India. Asian J Psychiatr. 2013;6:151–6.CrossRefPubMed
102.
Arbabi M, Ghodsi Z, Mahdanian A, Noormohammadi N, Shalileh K, Darvish F, et al. Mental health in patients with pemphigus: an issue to worth consideration. Indian J. Dermatol. [Internet]. Medknow Publications; 2011 [cited 2017 Apr 30];56:541–5. Available from: http://​www.​ncbi.​nlm.​nih.​gov/​pubmed/​22121274
103.
Tabolli S, Mozzetta A, Antinone V, Alfani S, Cianchini G, Abeni D. The health impact of pemphigus vulgaris and pemphigus foliaceus assessed using the medical outcomes study 36-item short form health survey questionnaire. Br. J. Dermatol. [Internet]. 2008;158:1029–34. Available from: http://​www.​ncbi.​nlm.​nih.​gov/​pubmed/​18294312
104.
Tabolli S, Pagliarello C, Paradisi A, Cianchini G, Giannantoni P, Abeni D. Burden of disease during quiescent periods in patients with pemphigus. Br J Dermatol. 2014;170:1087–91.CrossRefPubMed
105.
106.
Ren Z, Hsu DY, Brieva J, Silverberg NB, Langan SM, Silverberg JI. Hospitalization, inpatient burden and comorbidities associated with bullous pemphigoid in the U.S.A. Br J Dermatol. 2017;176:87–99.CrossRefPubMed
107.
Wohl Y, Dreiher J, Cohen AD. Pemphigus and osteoporosis: a case-control study. Arch Dermatol [Internet]. 2010;146:1126–31. Available from: file://o/Referenzmanager/Immunglobulin.PDFs/Wohl2010.pdf
108.
109.
110.
111.
Anhalt GJ. Paraneoplastic pemphigus. J. Investig. Dermatology Symp. Proc. 2004. p. 29–33.
112.
Kim SC, Kwon Y, Do LIJ, Lee IJ, Chang SN, Lee TG. cDNA cloning of the 210-kDa paraneoplastic pemphigus antigen reveals that envoplakin is a component of the antigen complex. J Invest Dermatol. 1997;109:365–9.CrossRefPubMed
113.
Mahoney MG, Aho S, Uitto J, Stanley JR. The members of the plakin family of proteins recognized by paraneoplastic pemphigus antibodies include periplakin. J Invest Dermatol. 1998;111:308–13.CrossRefPubMed
114.
Schepens I, Jaunin F, Begre N, Läderach U, Marcus K, Hashimoto T, et al. The protease inhibitor alpha-2-macroglobuline-like-1 is the p170 antigen recognized by paraneoplastic pemphigus autoantibodies in human. PLoS One. 2010;5(8).
115.
116.
117.
118.
119.
Ohzono A, Sogame R, Li X, Teye K, Tsuchisaka A, Numata S, et al. Clinical and immunological findings in 104 cases of paraneoplastic pemphigus. Br J Dermatol. 2015;173:1447–52.CrossRefPubMed
120.
121.
Liu Q, Bu DF, Li D, Zhu XJ. Genotyping of HLA-I and HLA-II alleles in Chinese patients with paraneoplastic pemphigus. Br J Dermatol. 2008;158:587–91.CrossRefPubMed
122.
Kaplan I, Hodak E, Ackerman L, Mimouni D, Anhalt GJ, Calderon S. Neoplasms associated with paraneoplastic pemphigus: a review with emphasis on non-hematologic malignancy and oral mucosal manifestations. Oral Oncol. 2004. p. 553–62.
123.
Joly P, Richard C, Gilbert D, Courville P, Chosidow O, Roujeau JC, et al. Sensitivity and specificity of clinical, histologic, and immunologic features in the diagnosis of paraneoplastic pemphigus. J Am Acad Dermatol. 2000;43:619–26.CrossRefPubMed
124.
125.
Nguyen VT, Ndoye A, Bassler KD, Shultz LD, Shields MC, Ruben BS, et al. Classification, clinical manifestations, and immunopathological mechanisms of the epithelial variant of paraneoplastic autoimmune multiorgan syndrome: a reappraisal of paraneoplastic pemphigus. Arch Dermatol. 2001;137:193–206.PubMed
126.
Czernik A, Camilleri M, Pittelkow MR, Grando SA. Paraneoplastic autoimmune multiorgan syndrome: 20 years after. Int. J. Dermatol. 2011. p. 905–14.
127.
128.
Maldonado F, Pittelkow MR, Ryu JH. Constrictive bronchiolitis associated with paraneoplastic autoimmune multi-organ syndrome. Respirology. 2009. p. 129–33.
129.
Nikolskaia OV, Nousari CH, Anhalt GJ. Paraneoplastic pemphigus in association with Castleman’s disease. Br J Dermatol. 2003;149:1143–51.CrossRefPubMed
130.
Tsuchisaka A, Numata S, Teye K, Natsuaki Y, Kawakami T, Takeda Y, et al. Epiplakin is a paraneoplastic pemphigus autoantigen and related to bronchiolitis obliterans in Japanese patients. J Invest Dermatol. 2016;136:399–408.CrossRefPubMed
131.
Jablonska S, Chorzelski TP, Beutner EH, Chorzelska J. Herpetiform pemphigus, a variable pattern of pemphigus. Int J Dermatol. 1975;14:353–9.CrossRefPubMed
132.
Kasperkiewicz M, Kowalewski C, Jabłońska S. Pemphigus herpetiformis: from first description until now. J Am Acad Dermatol. 2014;70:780–7.CrossRefPubMed
133.
Porro AM, Caetano de LVN, Maehara de LSN, dos Enokihara MMS. Non-classical forms of pemphigus: pemphigus herpetiformis, IgA pemphigus, paraneoplastic pemphigus and IgG/IgA pemphigus. An. Bras. Dermatol. 2014. p. 96–106.
134.
Robinson ND, Hashimoto T, Amagai M, Chan LS. The new pemphigus variants. J. Am. Acad. Dermatol. 1999. p. 649–71.
135.
Hocar O, Ait Sab I, Akhdari N, Hakkou M, Amal S. A case of pemphigus herpetiformis in a 12-year-old male. Int Sch Res Netw Pediatr. 2011;2011:1–4.
136.
Leithauser LA, Mutasim DF. A case of pemphigus herpetiformis occurring in a 9-year-old boy. Pediatr Dermatol. 2013;30:760–2.CrossRefPubMed
137.
Moutran R, Maatouk I, Stephan F, Halaby E, Abadjian G, Tomb R. Letter: Pemphigus herpetiformis of age of onset at 6 years. Dermatol Online J. 2011;17
138.
Maciejowska E, Jablonska S, Chorzelski T. Is pemphigus herpetiformis an entity? Int J Dermatol. 1987;26:571–7.CrossRefPubMed
139.
Santi CG, Maruta CW, Aoki V, Sotto MN, Rivitti EA, Diaz LA. Pemphigus herpetiformis is a rare clinical expression of nonendemic pemphigus foliaceus, fogo selvagem, and pemphigus vulgaris. J Am Acad Dermatol. 1996;34:40–6.CrossRefPubMed
140.
141.
Laws PM, Heelan K, Al-Mohammedi F, Walsh S, Shear NH. Pemphigus herpetiformis: a case series and review of the literature. Int J Dermatol. 2015;54:1014–22.CrossRefPubMed
142.
143.
Lebeau S, Müller R, Masouyé I, Hertl M, Borradori L. Pemphigus herpetiformis: analysis of the autoantibody profile during the disease course with changes in the clinical phenotype. Clin Exp Dermatol. 2010;35:366–72.CrossRefPubMed
144.
Palleschi GM, Giomi B. Herpetiformis pemphigus and lung carcinoma: a case of paraneoplastic pemphigus. Acta Derm. Venereol. 2002. p. 304–5.
145.
146.
Arranz D, Corral M, Prats I, López-Ayala E, Castillo C, Vidaurrázaga C, et al. Herpetiform pemphigus associated with esophageal carcinoma. Actas Dermosifiliogr. 2005. p. 119–21.
147.
148.
149.
Sanchez-Palacios C, Chan LS. Development of pemphigus herpetiformis in a patient with psoriasis receiving UV-light treatment. J Cutan Pathol. 2004;31:346–9.CrossRefPubMed
150.
Morita E, Amagai M, Tanaka T, Horiuchi K, Mizuno H, Yamamoto S. A case of herpetiform pemphigus coexisting with psoriasis vulgaris [6]. Br. J. Dermatol. 1999. p. 754–5.
151.
Marinović B, Basta-Juzbašić A, Bukvić-Mokos Z, Ľeović R, Lončrić D. Coexistence of pemphigus herpetiformis and systemic lupus erythematosus. J Eur Acad Dermatology Venereol. 2003;17:316–9.CrossRef
152.
Shimizu K, Hashimoto T, Wang N, Watanabe K, Ohata Y, Kikuchi A, et al. A case of herpetiform pemphigus associated with autoimmune hemolytic anemia: detection of autoantibodies against multiple epidermal antigens. Dermatology [Internet]. 1996 [cited 2017 Nov 20];192:179–82. Available from: http://​www.​ncbi.​nlm.​nih.​gov/​pubmed/​8829509
153.
Bull RH, Fallowfield ME, Marsden RA. Autoimmune blistering diseases associated with HIV infection. Clin Exp Dermatol. 1994;19:47–50.CrossRefPubMed
154.
Abe T, Kouno M, Yamamoto N, Mori O, Hashimoto T, Amagai M. A case of D-penicillamine induced herpetiform pemphigus. Nishinihon J Dermatol. 2003;65:126–9.CrossRef
155.
156.
Verdier-Sevrain S, Joly P, Thomine E, Belanyi P, Gilbert D, Tron F, et al. Thiopronine-induced herpetiform pemphigus: report of a case studied by immunoelectron microscopy and immunoblot analysis. Br. J. Dermatol. [Internet]. 1994 [cited 2017 Nov 20];130:238–40. Available from: http://​www.​ncbi.​nlm.​nih.​gov/​pubmed/​8123578
157.
Tsuruta D, Ishii N, Hamada T, Ohyama B, Fukuda S, Koga H, et al. IgA pemphigus. Clin Dermatol. 2011;29:437–42.CrossRefPubMed
158.
Geller S, Gat A, Zeeli T, Hafner A, Eming R, Hertl M, et al. The expanding spectrum of IgA pemphigus: a case report and review of the literature. Br. J. Dermatol. 2014. p. 650–6.
159.
Hodak E, David M, Ingber A, Rotem A, Hazaz B, Shamai-lubovitz O, et al. The clinical and histopathological spectrum of IgA-pemphigus—report of two cases. Clin Exp Dermatol. 1990;15:433–7.CrossRefPubMed
160.
Hashimoto T, Kiyokawa C, Mori O, Miyasato M, Chidgey MAJ, Garrod DR, et al. Human desmocollin 1 (Dsc1) is an autoantigen for the subcorneal pustular dermatosis type of IgA pemphigus. J. Invest. Dermatol. 1997;109:127–31.CrossRefPubMed
161.
Ishii N, Ishida-Yamamoto A, Hashimoto T. Immunolocalization of target autoantigens in IgA pemphigus. Clin Exp Dermatol. 2004;29:62–6.CrossRefPubMed
162.
163.
164.
165.
Kern J, Gehring W, Kreisel W, Hertl M, Technau-Hafsi K, Bruckner-Tuderman L, et al. Overlap of IgA pemphigus and linear IgA dermatosis in a patient with ulcerative colitis: a mere coincidence? Acta Derm. Venereol. [Internet]. 2014 [cited 2017 Jan 7];94:228–30. Available from: https://​doi.​org/​10.​2340/​00015555-1658
166.
167.
Papakonstantinou E, Kapp A, Jonkman MF, Raap U. Intraepidermal neutrophilic dermatosis type of IgA pemphigus with circulating linear IgA disease antibodies associated with ulcerative colitis. J. Eur. Acad. Dermatology Venereol. [Internet]. 2017 [cited 2017 Dec 2]; Available from: http://​www.​ncbi.​nlm.​nih.​gov/​pubmed/​28653439
168.
169.
170.
171.
Mimouni D, Bar H, Gdalevich M, Katzenelson V, David M. Pemphigus, analysis of 155 patients. J Eur Acad Dermatol Venereol. 2010;24:947–52.CrossRefPubMed
172.
Celere BS, Vernal S, Brochado, MJF, Segura-Muñoz SI, Roselino AM. Geographical foci and epidemiological changes of pemphigus vulgaris in four decades in Southeastern Brazil. Int. J. Dermatol. 2017. p. 1494–6.
173.
Kridin K, Zelber-Sagi S, Khamaisi M, Cohen AD, Bergman R. Remarkable differences in the epidemiology of pemphigus among two ethnic populations in the same geographic region. J Am Acad Dermatol. 2016;75:925–30.CrossRefPubMed
174.
Hahn K, Kippes W, Amagai M, Rzany B, Brocker EB, Zillikens D. Clinical aspects and immunopathology in 48 patients with pemphigus. Hautarzt [Internet]. 2000;51:670–7. Available from: file://o/Referenzmanager/Immunglobulin.PDFs/Hahn2000.pdf
175.
Amin MN, Islam AZMM. Clinical, histologic and immunologic features of pemphigus in Bangladesh. Int J Dermatol. 2006;45:1317–8.CrossRefPubMed
176.
Metadata
Title
Pemphigus group: overview, epidemiology, mortality, and comorbidities
Author
Khalaf Kridin
Publication date
01-04-2018
Publisher
Springer US
Published in
Immunologic Research / Issue 2/2018
Print ISSN: 0257-277X
Electronic ISSN: 1559-0755
DOI
https://doi.org/10.1007/s12026-018-8986-7

Other articles of this Issue 2/2018

Immunologic Research 2/2018 Go to the issue

Original Article

Phagocytosis and oxycytosis: two arms of human innate immunity

Original Article

Serum adenosine deaminase activity is increased in systemic lupus erythematosus patients and correlated with disease activity

Original Article

Chronic graft-specific cell-mediated immune response toward candidate xenogeneic biomaterial

Original Article

The human breast cancer-associated protein, the prolactin-inducible protein (PIP), regulates intracellular signaling events and cytokine production by macrophages

Original Article

Matrix-M™ adjuvant enhances immunogenicity of both protein- and modified vaccinia virus Ankara-based influenza vaccines in mice

Original Article

T cell receptor-β J usage, in combination with particular HLA class II alleles, correlates with better cancer survival rates